Acumen Pharmaceuticals revealed new data at AAIC 2026 showing their Enhanced Brain Delivery™ (EBD™) technology significantly improves brain penetration of Alzheimer’s antibodies, with candidate ACU401 achieving up to 40-fold greater exposure in key brain regions in primates. This advancement could enable lower doses and easier delivery methods, addressing a major challenge in Alzheimer’s treatment. Additionally, patient insights from the ALTITUDE-AD trial highlight the urgent need for effective early-stage therapies. Acumen plans to advance these candidates into clinical trials, aiming to improve outcomes for early Alzheimer’s disease patients.
Ares Capital has maintained a steady quarterly dividend of $0.48 per share for 12 consecutive quarters, marking 68 quarters of stable or increasing payouts. However, the dividend has not grown, and recent earnings per share have slightly dipped below...
The Invesco S&P 500 Revenue ETF (RWL) offers investors enhanced exposure to the consumer staples sector by weighting holdings based on revenue, favoring market leaders with high sales volumes. This approach has helped RWL outperform comparable ETFs l...
Jim Cramer advised retirees to reconsider holding high-growth stocks like Nvidia and Apple, suggesting 30-year U.S. Treasuries as a safer core investment due to their 5.35% risk-free yield. While stocks offer growth and dividends, their high valuatio...
Anthropic CEO Dario Amodei published an essay proposing a three-step plan for AI companies to deliberately slow the pace of improving AI models to ensure safety without sacrificing commercial advantage or U.S. leadership in AI. The plan includes gran...
Bitcoin ETFs experienced a fourth consecutive day of outflows, losing $13.29 million as Bitcoin's price remained around $77,000. In contrast, Ether ETFs attracted $216.41 million in net inflows, marking their fourth straight week of gains, led by Bla...
